Digital Therapeutics Company to Present Evidence at 5th Neurological Disorders Summit

The abstract, "Case study of utilization of digital therapeutics (JOGO) for post right MCA infarction" will be presented during the poster sessions on July 19, 2019 from 5-7 pm at  Salon D.

JOGO HEALTH to present evidence of digital therapeutics at ANZSCoS Annual Scientific Meeting

The poster, "Wireless EMG biofeedback for motor impairments" will be presented in the "Innovation" track.

First Digital Therapeutics Solution for Orthopedics Recovery to be presented at Clinical Orthopedics Society (COS) 2019 Annual Meeting

JOGO Health to present at HLTH, and GIANT Health

JOGO Health to present at HLTH, and GIANT Health

JOGO Health Announces Late Breaking Data at American Congress of Rehabilitation Medicine Scientific Meeting

Data Presented at ACRM 2019 Demonstrates Efficacy of JOGO to Successfully Treat Patients with Middle Cerebral Artery (MCA) Infarction


JOGO-Gx is FDA 510 (K) Exempt. FDA registration number.: 3016735640.

FDA Owner Operator Number: 10069814

US Group National Provider Number (NPI) 1013537349